CircuLex Anti-CML Human autoAntibody ELISA Kit

  • Applications
    • ELISA
  • Code # CY-8068
  • Size 96 Assays
  • Price


Reducing sugars react with protein amino groups to form a diverse group of protein-bound moieties with fluorescent and cross-linking properties. These compounds, called advanced glycosylation end products (AGEs), have been implicated in the structural and functional alterations of proteins that occur during aging and long-term diabetes. Although several AGE structures have been reported (1, 2), it was demonstrated that Nε -(carboxymethyl) lysine (CML) is a major antigenic AGE structure. CML concentration is also increased in patients who have diabetes with complications, including nephropathy (3–5), retinopathy (6), and atherosclerosis (7–9). CML is also recognized by receptor for AGE (RAGE), and CML-RAGE interaction activates cell signaling pathways such as NF-B and enhances the expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells (10). It has been postulated that AGE structures present in vivo could serve as an immunological epitope to raise autoantibodies against AGE structures, particularly CML. Shibayama et al. showed the presence of autoantibodies agaist AGE structures, particularly those against CML adduct in streptozotocin (STZ)-induced diabetic rats and patients with several diseases (11, 12). The autoantibody against CML adduct was higher in patients with renal failure than in normal subjects or diabetic patients without renal failure (11). These results suggest that autoantibody against CML might play a possible role in the development of diabetic nephropathy or chronic renal failure.
  • Application:
  • Components:
    • Microplate
    • 10X Wash Buffer
    • Dilution Buffer
    • Mouse Visfatin/PBEF Standard
    • HRP conjugated Detection Antibody
    • Substrate Reagent
    • Stop Solution 
  • Description:

    The CircuLex Anti-CML human autoantibody ELISA Kit is used for the semi-quantitative measurement of IgG class anti-CML/Nε-(carboxymethyl) lysine human autoantibody in human serum and plasma. It can be used for 96 Assays.

  • Product Type:
    ELISA Kit
  • Research Area:
  • Short Description:

    CircuLex Anti-CML Human autoAntibody ELISA Kit.

  • Size:
    96 Assays
  1. Koutroumani N et al. Protective mechanisms against oxidative stress and angiopathy in young patients with diabetes type 1 (DM1). 26, 309-17 (2013),
  2. Meloche J, et al., RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes. Arterioscler Thromb Vasc Biol. 31, 2114-2124 (2011)
  1. Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, Ueda S, Horiuchi S: Biochemistry 35: 8075 –8083,1996
  2. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW: Biochemistry 34: 10872 –10878,1995
  3. Makino H, Shikata K, Hironaka K, Kushiro M, Yamasaki Y, Sugimoto H, Ota Z, Araki N, Horiuchi S: Kidney Int 48: 517 –526,1995
  4. Suzuki D, Yagame M, Jinde K, Naka R, Yano N, Endoh M, Kaneshige H, Nomoto Y, Sakai H: J Diabetes Complications 10: 314 –319,1996
  5. Imai N, Nishi S, Suzuki Y, Karasawa R, Ueno M, Shimada H, Kawashima S, Nakamaru T, Miyakawa Y, Araki N, Horiuchi S, Gejyo F, Arakawa M: Nephron 76: 153 –160,1997
  6. Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S: Diabetologia 40: 764 –769,1997
  7. Kume S, Takeya M, Mori T, Araki N, Suzuki H, Horiuchi S, Kodama T, Miyauchi Y, Takahashi K: Am J Pathol. 147: 654 –667,1995
  8. Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, Horiuchi S, Itabe H, Takano T: Atherosclerosis 141: 61 –75,1998
  9. Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, Horiuchi S: Atherosclerosis 142: 67 –77,1999
  10. Kislinger T, Fu C, Huber B, Qu W, Taguichi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM: J Biol Chem 274: 31740 –31749,1999
  11. Shibayama R, Araki N, Nagai R, Horiuchi S.; Autoantibody against N(epsilon)-(carboxymethyl)lysine: an advanced glycation end product of the Maillard reaction. Diabetes. 1999 Sep;48(9):1842-9.
  12. Vay D, Vidali M, Allochis G, Cusaro C, Rolla R, Mottaran E, Bellomo G, Albano E.; Antibodies against advanced glycation end product Nepsilon-(carboxymethyl)lysine in healthy controls and diabetic patients. Diabetologia. 2000 Nov;43(11):1385-8.